Targeting Glioblastoma Stem Cells: A40s Aptamer-NIR-Dye Conjugate for Glioblastoma Visualization and Treatment

  • Alessandra Affinito
  • , Francesco Ingenito
  • , Sara Verde
  • , Emanuele Musella
  • , Birlipta Pattanayak
  • , Danilo Fiore
  • , Cristina Quintavalle
  • , Aurelia Fraticelli
  • , Martina Mascolo
  • , Gianluca Petrillo
  • , Claudia Pignataro
  • , Giada De Luca
  • , Laura Mezzanotte
  • , Gerolama Condorelli*
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Downloads (Pure)

Abstract

Glioblastoma (GBM) is the most aggressive and challenging brain cancer, in terms of diagnosis and therapy. The highly infiltrative glioblastoma stem cells (GSCs) are difficult to visualize and surgically remove with the current diagnostic tools, which often lead to misdiagnosis and false-positive results. In this study, we focused on a groundbreaking tool for specifically visualizing and removing GSCs. We exploited the specific binding of A40s aptamer to EphA2 for the selective delivery of Near-Infrared Dyes (NIR-Dyes), like IR700DX and ICG, both in vitro and in vivo. The A40s aptamer, engineered through the NIR-Dye conjugation, did not affect aptamer binding ability; indeed, A40s-NIR-Dye conjugates bound GLI261 stem-like cells and patient-derived GSCs in vitro; moreover, they induced cell death upon photodynamic therapy treatment (PDT). Additionally, when systemically administrated, the A40s-NIR-Dye conjugates allowed GSC visualization and accumulated in tumor mass. This allows GSCs detection and treatment. Our findings demonstrate the potential use of A40s aptamer as a targeted therapeutic approach and imaging tool in vivo for GSCs, paving the way for improved, more effective, and less invasive GBM management.

Original languageEnglish
Article number768
JournalBiomolecules
Volume15
Issue number6
DOIs
Publication statusPublished - 27 May 2025

Bibliographical note

Publisher Copyright:
© 2025 by the authors.

Fingerprint

Dive into the research topics of 'Targeting Glioblastoma Stem Cells: A40s Aptamer-NIR-Dye Conjugate for Glioblastoma Visualization and Treatment'. Together they form a unique fingerprint.

Cite this